Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference 

4-Hydroxynonenal (4-HNE) levels strongly correlate with rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and survival of patients from onset and diagnosis to death (91.7% sensitivity and 71.1% specificity).

4-HNE levels may serve as a potential surrogate biomarker to track efficacy of ALS disease modifying treatments, such as COYA 302.

On March 12, 2024, Coya Therapeutics, Inc. (Nasdaq: COYA, a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, MD, Chairman of Coya’s Scientific Advisory Board and Dr. David Beers, PhD, Associate Research Professor of Neurology, Houston Methodist, will present biomarker data as part of a panel presentation at the Society of Neuroimmune Pharmacology Conference. The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort. An additional analysis of another random 50 patients from the same patient registry cohort is being finalized and will be presented in the future. In a proof-of-concept study in patients with ALS, the combination of low dose interleukin-2 (LD IL-2) and CTLA-4 Ig appeared to lower 4-HNE and other proinflammatory biomarker levels. Coya intends to finalize the analysis of the initial 50 patients, as well as the additional 50 ALS patients, and publish the results in a peer review journal in the near future. Furthermore, Coya has filed patent applications relating to the use of the biomarker in ALS. The biomarker data can be viewed here.

Login Or Register To Read Full Story